<!DOCTYPE html SYSTEM "about:legacy-compat"><html lang="en-US" data-colors-preset="contrast" data-primary-color="#307FFF"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"><meta charset="UTF-8"><meta name="robots" content="noindex">  <meta name="built-on" content="2024-01-01T13:15:31.7257097"><meta name="build-number" content="${buildNumber}">       <title>阿斯利康罕见病药物在中国获批第四个适应证 | 2023-10-18</title><script id="virtual-toc-data" type="application/json">[]</script><script id="topic-shortcuts" type="application/json"></script><link href="https://resources.jetbrains.com/writerside/apidoc/6.6.6-b205/app.css" rel="stylesheet">   <link rel="apple-touch-icon" sizes="180x180" href="https://jetbrains.com/apple-touch-icon.png"><link rel="icon" type="image/png" sizes="32x32" href="https://jetbrains.com/favicon-32x32.png"><link rel="icon" type="image/png" sizes="16x16" href="https://jetbrains.com/favicon-16x16.png"><link rel="manifest" href="https://jetbrains.com/site.webmanifest"><link rel="mask-icon" href="https://jetbrains.com/safari-pinned-tab.svg" color="#000000"><meta name="msapplication-TileColor" content="#000000"/><meta name="msapplication-TileImage" content="https://resources.jetbrains.com/storage/ui/favicons/mstile-144x144.png"/><meta name="msapplication-square70x70logo" content="https://resources.jetbrains.com/storage/ui/favicons/mstile-70x70.png"/><meta name="msapplication-square150x150logo" content="https://resources.jetbrains.com/storage/ui/favicons/mstile-150x150.png"/><meta name="msapplication-wide310x150logo" content="https://resources.jetbrains.com/storage/ui/favicons/mstile-310x150.png"/><meta name="msapplication-square310x310logo" content="https://resources.jetbrains.com/storage/ui/favicons/mstile-310x310.png"/>  <meta name="image" content=""><!-- Open Graph --><meta property="og:title" content="阿斯利康罕见病药物在中国获批第四个适应证 | 2023-10-18"/><meta property="og:description" content=""/><meta property="og:image" content=""/><meta property="og:site_name" content="2023-10-18 Help"/><meta property="og:type" content="website"/><meta property="og:locale" content="en_US"/><meta property="og:url" content="8449.html"/><!-- End Open Graph --><!-- Twitter Card --><meta name="twitter:card" content="summary_large_image"><meta name="twitter:site" content=""><meta name="twitter:title" content="阿斯利康罕见病药物在中国获批第四个适应证 | 2023-10-18"><meta name="twitter:description" content=""><meta name="twitter:creator" content=""><meta name="twitter:image:src" content=""><!-- End Twitter Card --><!-- Schema.org WebPage --><script type="application/ld+json"> { "@context": "http://schema.org", "@type": "WebPage", "@id": "8449.html#webpage", "url": "8449.html", "name": "阿斯利康罕见病药物在中国获批第四个适应证 | 2023-10-18", "description": "", "image": "", "inLanguage":"en-US" }</script><!-- End Schema.org --><!-- Schema.org WebSite --><script type="application/ld+json"> { "@type": "WebSite", "@id": "/#website", "url": "/", "name": "2023-10-18 Help" }</script><!-- End Schema.org --></head>      <body data-id="8449" data-main-title="阿斯利康罕见病药物在中国获批第四个适应证" data-article-props="{&quot;seeAlsoStyle&quot;:&quot;links&quot;}"  data-template="article"  data-breadcrumbs=""  >   <div class="wrapper"><main class="panel _main"><header class="panel__header"><div class="container"><h3>2023-10-18  Help</h3><div class="panel-trigger"></div></div></header><section class="panel__content"><div class="container"><article class="article" data-shortcut-switcher="inactive"><h1 data-toc="8449"   id="8449.md">阿斯利康罕见病药物在中国获批第四个适应证</h1>  <p id="efe86091_7"><span class="control" id="efe86091_8">界面快报</span></p><p id="efe86091_9"><span class="control" id="efe86091_10">2023-10-18 10:44</span></p><p id="efe86091_11"><span class="control" id="efe86091_12">https://www.jiemian.com/article/10248570.html</span></p><p id="efe86091_13">10月18日，据阿斯利康中国官网，中国国家药品监督管理局批准依库珠单抗（eculizumab）注射液（商品名：舒立瑞&reg;，Soliris&reg;）用于治疗抗水通道蛋白4（AQP4）抗体阳性的视神经脊髓炎谱系疾病（NMOSD）成人患者。依库珠单抗是中国首个也是唯一一个获批用于治疗NMOSD的补体抑制剂。</p><p id="efe86091_14">NMOSD是一种罕见的、令人衰弱的中枢神经系统自身免疫性疾病，主要累及视神经和脊髓。根据现有数据推断，目前中国约有27,000名成人确诊患有NMOSD8。</p><p id="efe86091_15">目前，依库珠单抗已在中国获批用于治疗成人及儿童阵发性睡眠性血红蛋白尿症（PNH）、非典型溶血性尿毒症综合征（aHUS）和成人抗乙酰胆碱受体（AChR）抗体阳性的难治性全身型重症肌无力（gMG），并已在全球多个国家获批多项适应症。</p><div class="last-modified"> Last modified: 01 一月 2024</div><div data-feedback-placeholder="true"></div><div class="navigation-links _bottom">  <a class="navigation-links__prev" href="8450.html">因接到炸弹袭击威胁警报，法国六个机场紧急疏散</a>   <a class="navigation-links__next" href="8448.html">进驻过半，二十届中央第二轮巡视已进驻17家单位</a>  </div></article><div id="disqus_thread"></div></div></section></main></div>  <script src="https://resources.jetbrains.com/writerside/apidoc/6.6.6-b205/app.js"></script></body></html>